Welzin M Syrup is a combination medication containing Levocetirizine 2.5 mg and Montelukast 4 mg, formulated for the management of allergic conditions. Levocetirizine, a third-generation non-sedative antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms such as sneezing, rhinorrhea, nasal congestion, and pruritus associated with allergic rhinitis and chronic urticaria. Montelukast, a leukotriene receptor antagonist, blocks cysteinyl leukotriene receptors, mitigating inflammation and bronchoconstriction commonly observed in asthma and allergic rhinitis. The synergistic effect of these agents provides comprehensive relief from allergic manifestations by targeting multiple inflammatory pathways. Welzin M Syrup is indicated for pediatric patients requiring effective control of seasonal allergic rhinitis, perennial allergic rhinitis, and mild to moderate asthma symptoms. It is generally well-tolerated, with a low incidence of adverse effects such as headache, fatigue, or gastrointestinal discomfort. Dosage should be individualized based on age and clinical response, and administration should follow medical guidance. Caution is advised in patients with hepatic or renal impairment, and potential drug interactions should be considered. Welzin M Syrup offers a convenient oral formulation to improve compliance in children requiring combination therapy for allergic respiratory conditions.